Portal de investigación
Antimicrobial Defined Daily Dose in Neonatal Population: Validation in the Clinical Practice.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Villanueva-Bueno, Cristina
- Montecatine-Alonso, Elena
- Jimenez-Parrilla, Francisco
- Gonzalez-Lopez, Maria
- Manrique-Rodriguez, Silvia
- Moreno-Ramos, Francisco
- Canete-Ramirez, Carme
- Dolz, Elisenda
- Caro-Teller, Jose Manuel
- Moral-Pumarega, Maria Teresa
- Bergon-Sendin, Elena
- Gómez-Trevecedo Calvo MT
- Gallego-Fernandez, Carmen
- Vayo-Benito, Concepcion Alvarez Del
- Mejias-Trueba, Marta
- Gil-Navarro, Maria Victoria
- Paediatric Antimicrobial Defined Daily Dose Study Group KiDDDs
Grupos
Abstract
BACKGROUND: Currently, there is no validated method for estimating antimicrobial consumption in the neonatal population, as it exists for adults using Defined Daily Doses (DDD). In neonatology, although there are different methods, each one with advantages and disadvantages, there is no unified criterion for use. The aim of this study is to validate the neonatal DDD designed as a new standardised form of antimicrobial consumption over this population. METHODS: The validation of the neonatal DDD, Phase II of the research project, was carried out through a descriptive observational study. Periodic cut-offs were performed to collect antimicrobial prescriptions of neonates admitted to the neonatology and intensive care units of nine Spanish hospitals. The data collected included demographic variables (gestational age, postnatal age, weight and sex), antimicrobial dose, frequency and route of administration. The selection of the optimal DDD value takes into account power value, magnitude obtained from the differences in the DDD, statistical significance obtained by the Wilcoxon test and degree of agreement in the stipulated doses. RESULTS: Set of 904 prescriptions were collected and finally 860 were analysed based on the established criteria. The antimicrobials were mostly prescribed in the intensive care unit (63.1%). 32 different antimicrobials were collected, and intravenous administration was the most commonly used route. Neonatal DDD were defined for 11 different antimicrobials. A potency > 80% was obtained in 7 antibiotics. The 57.1% of the selected DDD correspond to phase I and 21.4% from phase II. CONCLUSION: DDD validation has been achieved for the majority of intravenously administered antimicrobials used in clinical practice in the neonatal population. This will make it possible to have an indicator that will be used globally to estimate the consumption of antimicrobials in this population, thus confirming its usefulness and applicability.
Datos de la publicación
- ISSN/ISSNe:
- 2079-6382, 2079-6382
- Tipo:
- Article
- Páginas:
- -
- Factor de Impacto:
- 0,785 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
ANTIBIOTICS-BASEL Multidisciplinary Digital Publishing Institute (MDPI)
Documentos
- No hay documentos
Filiaciones
Keywords
- antimicrobial consumption; antimicrobial management; daily-defined dosage; neonatal antimicrobial prescription; neonatal infections
Proyectos asociados
MULTICENTER, RANDOMIZED, BLINDED CLINICAL STUDY COMPARING EARLY USE OF TOTAL BODY MODERATE HYPOTHERMIA PLUS TOPIRAMATE OR PLACEBO IN ASPHYXIATED NEWBORN INFANTS EVOLVING TO MODERATE-TO-SEVERE HYPOXIC ISCHEMIC ENCEPHALOPATHY
Investigador Principal: MÁXIMO VENTO TORRES
EC11-244 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2012
RED DE SALUD MATERNO INFANTIL Y DEL DESARROLLO
Investigador Principal: MÁXIMO VENTO TORRES
RD12/0026/0012 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013
RED DE SALUD MATERNO-INFANTIL Y DEL DESARROLLO.
Investigador Principal: MÁXIMO VENTO TORRES
RD16/0022/0001 . INSTITUTO DE SALUD CARLOS III . 2017
Paracetamol versus ibuprofeno en recién nacidos prematuros con diagnóstico de ductus arterioso persistente hemodinamicamente significativo: ensayo clínico aleatorizado.
Investigador Principal: MARTA AGUAR CARRASCOSA
PI18/01696 . INSTITUTO DE SALUD CARLOS III . 2019
EFECTO DEL ALOPURINOL EN PACIENTES CON ENCEFALOPATÍA HIPÓXICO-ISQUÉMICA TRATADOS CON HIPOTERMIA – ALBINO – ENSAYO CLÍNICO MULTICÉNTRICO, ALEATORIZADO, CIEGO, CONTROLADO CON PLACEBO.
Investigador Principal: MÁXIMO VENTO TORRES
ALBINO . 2018
ESTUDIO SOBRE LA UTILIZACIÓN DE MEDICAMENTOS EN CONDICIONES OFF-LABEL Y UNLICENSED EN UNA UNIDAD DE CUIDADOS INTENSIVOS NEONATALES.
Investigador Principal: PILAR SÁENZ GONZÁLEZ
GIP-MED-2017-01 . 2017
IDENTIFICACIÓN DE FACTORES CLÍNICOS, MOLECULARES Y RADIOLÓGICOS PREDICTORES DE RESPUESTA AL TRATAMIENTO CON BEVACIZUMAB EN PACIENTES CON GLIOMAS DE ALTO GRADO: BEVA-GLIO.
Investigador Principal: ANA ALEJANDRA GARCÍA ROBLES
AGR-BEV-2018-01 . 2018
ENSAYO CLÍNICO FASE I PARA ESTABLECER LA SEGURIDAD DEL USO DE CÉLULAS MESENQUIMALES TRONCALES FETALES ALOGÉNICAS DE CORDÓN UMBILICAL EXPANDIDAS EN PACIENTES PREMATUROS CON DISPLASIA BRONCOPULMONAR.
Investigador Principal: MÁXIMO VENTO TORRES
PULMESCEL-1 . 2019
PARACETAMOL VERSUS IBUPROFENO EN RECIÉN NACIDOS PREMATUROS CON DIAGNÓSTICO DE DUCTUS ARTERIOSO PERSISTENTE HEMODINÁMICAMENTE SIGNIFICATIVO: ENSAYO CLÍNICO ALEATORIZADO.
Investigador Principal: MARTA AGUAR CARRASCOSA
IBUPAR-TRIAL . 2017
DISEÑO Y VALIDACIÓN DE LAS DOSIS DIARIAS DEFINIDAS DE ANTIMICROBIANOS EN POBLACIÓN PEDIÁTRICA.
Investigador Principal: ANA ALEJANDRA GARCÍA ROBLES
GAF-TEI-2015-01 . 2021
Proyecto Identity: Identificación de pacientes por biometría de voz en farmacia externa hospitalaria.
Investigador Principal: JOSÉ LUIS POVEDA ANDRÉS
BIOVOZ-2022-01 . 2023
Cita
Villanueva C,Montecatine E,Jimenez F,Gonzalez M,Manrique S,Moreno F,Canete C,Dolz E,Garcia A,Caro JM,Moral MT,Bergon E,Gómez MT,Gallego C,Vayo CAD,Mejias M,Gil MV,Paediatric Antimicrobial Defined Daily Dose Study Group K. Antimicrobial Defined Daily Dose in Neonatal Population: Validation in the Clinical Practice. Antibiotics (Basel). 2023. 12. (3):602. IF:4,300. (1).